Fulgent Boston Consulting Group Matrix
Unlock Strategic Clarity
Curious where Fulgent’s products sit — Stars, Cash Cows, Dogs or Question Marks? This preview hints at the shifts; the full Fulgent BCG Matrix delivers quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel files so you can decide where to invest, divest or double down. Purchase the complete report and move from guesswork to a focused strategy.
Stars
Oncology NGS panels
Oncology NGS panels sit in the Stars quadrant—high-growth 2024 market as clinicians demand actionable tumor profiling now. Fulgent’s breadth and fast TAT (often under 7 days) keep orders sticky, driving share gains where access and reimbursement are solid. Growth still requires marketing-heavy effort to win tumor boards and pathways. Keep fueling adoption to cement leadership and scale.
Rare disease exome/genome diagnostics
Trio exome and rapid WES/WGS are rapidly becoming first-line for undiagnosed disease, with reported diagnostic yields of ~25–40% and rapid WGS turnarounds described as low as 7 days. Strong bioinformatics and routine reanalysis (adds ~10% incremental yield) win specialists and drive referrals. Volume is rising, but interpretation and genetic counseling materially increase per-case support costs (often a double-digit percent of total cost). Invest to hold lead—this can mature into a cash cow as guideline adoption hardens.
Expanded carrier screening (NGS-based)
Expanded carrier screening (NGS-based) is a Star as OB channels grow and ACOG guidance since 2021 supports population screening, driving bundled panels toward standard of care. NGS panels routinely detect over 90% of known pathogenic variants for targeted genes, and where Fulgent has payer contracts its faster turnaround and coverage create a conversion edge. Education and patient-access programs require dedicated budgets to scale; locking health-system pathways now will convert uptake into durable share.
Hospital/health-system genomics partnerships
Hospital/health-system genomics partnerships drive rapid share growth once embedded workflows and EMR integrations go live, with implementations in 2024 reporting double-digit increases in ordering and a faster ramp to preferred vendor status. These relationships expand menu adoption across oncology, reproductive health, and rare disease panels but require upfront integration resources and white-glove support. Once entrenched churn is low and volumes compound, creating durable revenue streams.
- EMR-integrated ordering: double-digit uplift post-live
- Menu breadth: oncology, reproductive, rare disease cross-sell
- Upfront cost: high implementation & support
- Durability: low churn, compounding volumes
Actionable reporting + clinician portal
Actionable reporting plus a clinician portal delivers a clean UX, embedded evidence links, and rapid variant updates that differentiate Fulgent in bids where clinician experience often tips decisions; 2024 adoption rose ~28% year-over-year in target hospital networks, and continuous enhancement—though costly—drives loyalty in fast-growing genomics segments.
- Clean UX: boosts clinician efficiency
- Evidence links: improves interpretation confidence
- Rapid variant updates: reduces time-to-action
- Continuous shipping: sustains default status
Oncology NGS: TAT under 7 days, WES/WGS yields 25–40%, adoption up 28%
Oncology NGS: high-growth 2024 market, TAT often <7 days; Trio exome/rapid WES/WGS diagnostic yield ~25–40% with reanalysis adding ~10% yield; expanded carrier screening adoption rising after ACOG guidance; hospital EMR integrations show double-digit uplifts and target-network adoption rose ~28% YoY in 2024.
| Metric | 2024 Value |
|---|---|
| Oncology TAT | <7 days |
| Trio/WES/WGS yield | 25–40% |
| Reanalysis uplift | ~10% |
| Adoption YoY | ~28% |
What is included in the product
Detailed Word Document
Targeted BCG matrix review of Fulgent’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page BCG matrix that pinpoints priorities fast, cutting analysis time and easing strategic decisions.
Cash Cows
Hereditary cancer germline panels
Hereditary cancer germline panels sit in Fulgent's cash-cow quadrant amid mature demand and high clinician/patient awareness, with clinical guidelines (NCCN and others) remaining stable through 2024. With payer and institutional contracts in place, margins are solid and operations efficient, requiring only modest promotional spend to hold share. The segment generated steady cash flow that can fund next-wave growth bets; the hereditary testing market was about USD 2.0 billion in 2024.
Routine single-gene and small panels
Automated pipelines and low COGS make routine single-gene and small panels dependable earners for Fulgent, delivering steady per-test profitability. Growth is flat but utilization remains consistent from community clinics, reducing revenue volatility. Minimal selling is needed beyond account maintenance and provider relations. Tightening batching and logistics can incrementally lift margins by reducing idle runs and reagent waste.
Cytogenetics/confirmatory assays (NGS-first adjacents)
Cytogenetics and confirmatory assays accompany NGS-first panels as ancillary tests, driving predictable volumes and often reimbursed when medically necessary (typical reimbursement ranges cited industrywide in 2024: $300–1,200 per assay). Market growth is limited—mid-single-digit CAGR—while operational repeatability exceeds 90%, enabling high throughput. Focus on quality and cost control yields straightforward, low-variance cash flow for Fulgent.
Established OB/GYN and oncology account base
Established OB/GYN and oncology account base acts as a cash cow: loyal practices keep ordering the core menu with a 2024 repeat-order rate above 90%, so relationship management outperforms heavy marketing; revenue is stable and churn is low when service and SLAs remain consistent; protect price and harvest cash flows.
- Focus: relationship management over broad marketing
- Ops: maintain SLAs, minimize churn
- Finance: protect pricing, maximize cash extraction
Reanalysis/updated reports on legacy cases
Reanalysis/updated reports on legacy cases are cash cows: small lab effort delivers meaningful incremental billing where payers permit, with 2024 internal metrics showing ~200 USD average incremental charge and ~15% incremental revenue on eligible cohorts; clinicians value new insights without fresh samples and demand is steady, so systematize reminders and billing to keep the flywheel turning.
- Effort: low
- Incremental billing: ~200 USD (2024)
- Revenue uplift: ~15% (2024 cohorts)
- Demand: steady; automate reminders/billing
Hereditary germline panels: stable margins, USD 2.0B market, steady per-test profit
Hereditary germline panels are Fulgent cash cows amid stable 2024 guidelines; market ~USD 2.0B (2024) and high clinician awareness sustain margins. Routine small panels deliver steady per-test profitability with low COGS; utilization is flat but reliable. Ancillary cytogenetics reimburse $300–1,200 (2024); reanalysis yields ~USD 200 average incremental charge (~15% uplift).
| Segment | 2024 metric | Margin/notes |
|---|---|---|
| Hereditary panels | Market USD 2.0B | High awareness, stable demand |
| Small panels | Flat growth | Low COGS, steady profit |
| Cytogenetics | Reimb USD 300–1,200 | Predictable volumes |
| Reanalysis | ~USD 200 avg | ~15% revenue uplift |
What You See Is What You Get
Fulgent BCG Matrix
The file you’re previewing is the exact Fulgent BCG Matrix you’ll receive after purchase — no watermarks, no demo slides, just the finished, professionally formatted report. It’s built for immediate use: edit, print, or drop straight into your pitch deck without fuss. Once bought, the same document is delivered to your inbox, ready for strategic planning or client presentations. No surprises, just clean, market-tested analysis you can act on.
Unlock Strategic Clarity
Curious where Fulgent’s products sit — Stars, Cash Cows, Dogs or Question Marks? This preview hints at the shifts; the full Fulgent BCG Matrix delivers quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel files so you can decide where to invest, divest or double down. Purchase the complete report and move from guesswork to a focused strategy.
Stars
Oncology NGS panels
Oncology NGS panels sit in the Stars quadrant—high-growth 2024 market as clinicians demand actionable tumor profiling now. Fulgent’s breadth and fast TAT (often under 7 days) keep orders sticky, driving share gains where access and reimbursement are solid. Growth still requires marketing-heavy effort to win tumor boards and pathways. Keep fueling adoption to cement leadership and scale.
Rare disease exome/genome diagnostics
Trio exome and rapid WES/WGS are rapidly becoming first-line for undiagnosed disease, with reported diagnostic yields of ~25–40% and rapid WGS turnarounds described as low as 7 days. Strong bioinformatics and routine reanalysis (adds ~10% incremental yield) win specialists and drive referrals. Volume is rising, but interpretation and genetic counseling materially increase per-case support costs (often a double-digit percent of total cost). Invest to hold lead—this can mature into a cash cow as guideline adoption hardens.
Expanded carrier screening (NGS-based)
Expanded carrier screening (NGS-based) is a Star as OB channels grow and ACOG guidance since 2021 supports population screening, driving bundled panels toward standard of care. NGS panels routinely detect over 90% of known pathogenic variants for targeted genes, and where Fulgent has payer contracts its faster turnaround and coverage create a conversion edge. Education and patient-access programs require dedicated budgets to scale; locking health-system pathways now will convert uptake into durable share.
Hospital/health-system genomics partnerships
Hospital/health-system genomics partnerships drive rapid share growth once embedded workflows and EMR integrations go live, with implementations in 2024 reporting double-digit increases in ordering and a faster ramp to preferred vendor status. These relationships expand menu adoption across oncology, reproductive health, and rare disease panels but require upfront integration resources and white-glove support. Once entrenched churn is low and volumes compound, creating durable revenue streams.
- EMR-integrated ordering: double-digit uplift post-live
- Menu breadth: oncology, reproductive, rare disease cross-sell
- Upfront cost: high implementation & support
- Durability: low churn, compounding volumes
Actionable reporting + clinician portal
Actionable reporting plus a clinician portal delivers a clean UX, embedded evidence links, and rapid variant updates that differentiate Fulgent in bids where clinician experience often tips decisions; 2024 adoption rose ~28% year-over-year in target hospital networks, and continuous enhancement—though costly—drives loyalty in fast-growing genomics segments.
- Clean UX: boosts clinician efficiency
- Evidence links: improves interpretation confidence
- Rapid variant updates: reduces time-to-action
- Continuous shipping: sustains default status
Oncology NGS: TAT under 7 days, WES/WGS yields 25–40%, adoption up 28%
Oncology NGS: high-growth 2024 market, TAT often <7 days; Trio exome/rapid WES/WGS diagnostic yield ~25–40% with reanalysis adding ~10% yield; expanded carrier screening adoption rising after ACOG guidance; hospital EMR integrations show double-digit uplifts and target-network adoption rose ~28% YoY in 2024.
| Metric | 2024 Value |
|---|---|
| Oncology TAT | <7 days |
| Trio/WES/WGS yield | 25–40% |
| Reanalysis uplift | ~10% |
| Adoption YoY | ~28% |
What is included in the product
Detailed Word Document
Targeted BCG matrix review of Fulgent’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page BCG matrix that pinpoints priorities fast, cutting analysis time and easing strategic decisions.
Cash Cows
Hereditary cancer germline panels
Hereditary cancer germline panels sit in Fulgent's cash-cow quadrant amid mature demand and high clinician/patient awareness, with clinical guidelines (NCCN and others) remaining stable through 2024. With payer and institutional contracts in place, margins are solid and operations efficient, requiring only modest promotional spend to hold share. The segment generated steady cash flow that can fund next-wave growth bets; the hereditary testing market was about USD 2.0 billion in 2024.
Routine single-gene and small panels
Automated pipelines and low COGS make routine single-gene and small panels dependable earners for Fulgent, delivering steady per-test profitability. Growth is flat but utilization remains consistent from community clinics, reducing revenue volatility. Minimal selling is needed beyond account maintenance and provider relations. Tightening batching and logistics can incrementally lift margins by reducing idle runs and reagent waste.
Cytogenetics/confirmatory assays (NGS-first adjacents)
Cytogenetics and confirmatory assays accompany NGS-first panels as ancillary tests, driving predictable volumes and often reimbursed when medically necessary (typical reimbursement ranges cited industrywide in 2024: $300–1,200 per assay). Market growth is limited—mid-single-digit CAGR—while operational repeatability exceeds 90%, enabling high throughput. Focus on quality and cost control yields straightforward, low-variance cash flow for Fulgent.
Established OB/GYN and oncology account base
Established OB/GYN and oncology account base acts as a cash cow: loyal practices keep ordering the core menu with a 2024 repeat-order rate above 90%, so relationship management outperforms heavy marketing; revenue is stable and churn is low when service and SLAs remain consistent; protect price and harvest cash flows.
- Focus: relationship management over broad marketing
- Ops: maintain SLAs, minimize churn
- Finance: protect pricing, maximize cash extraction
Reanalysis/updated reports on legacy cases
Reanalysis/updated reports on legacy cases are cash cows: small lab effort delivers meaningful incremental billing where payers permit, with 2024 internal metrics showing ~200 USD average incremental charge and ~15% incremental revenue on eligible cohorts; clinicians value new insights without fresh samples and demand is steady, so systematize reminders and billing to keep the flywheel turning.
- Effort: low
- Incremental billing: ~200 USD (2024)
- Revenue uplift: ~15% (2024 cohorts)
- Demand: steady; automate reminders/billing
Hereditary germline panels: stable margins, USD 2.0B market, steady per-test profit
Hereditary germline panels are Fulgent cash cows amid stable 2024 guidelines; market ~USD 2.0B (2024) and high clinician awareness sustain margins. Routine small panels deliver steady per-test profitability with low COGS; utilization is flat but reliable. Ancillary cytogenetics reimburse $300–1,200 (2024); reanalysis yields ~USD 200 average incremental charge (~15% uplift).
| Segment | 2024 metric | Margin/notes |
|---|---|---|
| Hereditary panels | Market USD 2.0B | High awareness, stable demand |
| Small panels | Flat growth | Low COGS, steady profit |
| Cytogenetics | Reimb USD 300–1,200 | Predictable volumes |
| Reanalysis | ~USD 200 avg | ~15% revenue uplift |
What You See Is What You Get
Fulgent BCG Matrix
The file you’re previewing is the exact Fulgent BCG Matrix you’ll receive after purchase — no watermarks, no demo slides, just the finished, professionally formatted report. It’s built for immediate use: edit, print, or drop straight into your pitch deck without fuss. Once bought, the same document is delivered to your inbox, ready for strategic planning or client presentations. No surprises, just clean, market-tested analysis you can act on.
Description
Unlock Strategic Clarity
Curious where Fulgent’s products sit — Stars, Cash Cows, Dogs or Question Marks? This preview hints at the shifts; the full Fulgent BCG Matrix delivers quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel files so you can decide where to invest, divest or double down. Purchase the complete report and move from guesswork to a focused strategy.
Stars
Oncology NGS panels
Oncology NGS panels sit in the Stars quadrant—high-growth 2024 market as clinicians demand actionable tumor profiling now. Fulgent’s breadth and fast TAT (often under 7 days) keep orders sticky, driving share gains where access and reimbursement are solid. Growth still requires marketing-heavy effort to win tumor boards and pathways. Keep fueling adoption to cement leadership and scale.
Rare disease exome/genome diagnostics
Trio exome and rapid WES/WGS are rapidly becoming first-line for undiagnosed disease, with reported diagnostic yields of ~25–40% and rapid WGS turnarounds described as low as 7 days. Strong bioinformatics and routine reanalysis (adds ~10% incremental yield) win specialists and drive referrals. Volume is rising, but interpretation and genetic counseling materially increase per-case support costs (often a double-digit percent of total cost). Invest to hold lead—this can mature into a cash cow as guideline adoption hardens.
Expanded carrier screening (NGS-based)
Expanded carrier screening (NGS-based) is a Star as OB channels grow and ACOG guidance since 2021 supports population screening, driving bundled panels toward standard of care. NGS panels routinely detect over 90% of known pathogenic variants for targeted genes, and where Fulgent has payer contracts its faster turnaround and coverage create a conversion edge. Education and patient-access programs require dedicated budgets to scale; locking health-system pathways now will convert uptake into durable share.
Hospital/health-system genomics partnerships
Hospital/health-system genomics partnerships drive rapid share growth once embedded workflows and EMR integrations go live, with implementations in 2024 reporting double-digit increases in ordering and a faster ramp to preferred vendor status. These relationships expand menu adoption across oncology, reproductive health, and rare disease panels but require upfront integration resources and white-glove support. Once entrenched churn is low and volumes compound, creating durable revenue streams.
- EMR-integrated ordering: double-digit uplift post-live
- Menu breadth: oncology, reproductive, rare disease cross-sell
- Upfront cost: high implementation & support
- Durability: low churn, compounding volumes
Actionable reporting + clinician portal
Actionable reporting plus a clinician portal delivers a clean UX, embedded evidence links, and rapid variant updates that differentiate Fulgent in bids where clinician experience often tips decisions; 2024 adoption rose ~28% year-over-year in target hospital networks, and continuous enhancement—though costly—drives loyalty in fast-growing genomics segments.
- Clean UX: boosts clinician efficiency
- Evidence links: improves interpretation confidence
- Rapid variant updates: reduces time-to-action
- Continuous shipping: sustains default status
Oncology NGS: TAT under 7 days, WES/WGS yields 25–40%, adoption up 28%
Oncology NGS: high-growth 2024 market, TAT often <7 days; Trio exome/rapid WES/WGS diagnostic yield ~25–40% with reanalysis adding ~10% yield; expanded carrier screening adoption rising after ACOG guidance; hospital EMR integrations show double-digit uplifts and target-network adoption rose ~28% YoY in 2024.
| Metric | 2024 Value |
|---|---|
| Oncology TAT | <7 days |
| Trio/WES/WGS yield | 25–40% |
| Reanalysis uplift | ~10% |
| Adoption YoY | ~28% |
What is included in the product
Detailed Word Document
Targeted BCG matrix review of Fulgent’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page BCG matrix that pinpoints priorities fast, cutting analysis time and easing strategic decisions.
Cash Cows
Hereditary cancer germline panels
Hereditary cancer germline panels sit in Fulgent's cash-cow quadrant amid mature demand and high clinician/patient awareness, with clinical guidelines (NCCN and others) remaining stable through 2024. With payer and institutional contracts in place, margins are solid and operations efficient, requiring only modest promotional spend to hold share. The segment generated steady cash flow that can fund next-wave growth bets; the hereditary testing market was about USD 2.0 billion in 2024.
Routine single-gene and small panels
Automated pipelines and low COGS make routine single-gene and small panels dependable earners for Fulgent, delivering steady per-test profitability. Growth is flat but utilization remains consistent from community clinics, reducing revenue volatility. Minimal selling is needed beyond account maintenance and provider relations. Tightening batching and logistics can incrementally lift margins by reducing idle runs and reagent waste.
Cytogenetics/confirmatory assays (NGS-first adjacents)
Cytogenetics and confirmatory assays accompany NGS-first panels as ancillary tests, driving predictable volumes and often reimbursed when medically necessary (typical reimbursement ranges cited industrywide in 2024: $300–1,200 per assay). Market growth is limited—mid-single-digit CAGR—while operational repeatability exceeds 90%, enabling high throughput. Focus on quality and cost control yields straightforward, low-variance cash flow for Fulgent.
Established OB/GYN and oncology account base
Established OB/GYN and oncology account base acts as a cash cow: loyal practices keep ordering the core menu with a 2024 repeat-order rate above 90%, so relationship management outperforms heavy marketing; revenue is stable and churn is low when service and SLAs remain consistent; protect price and harvest cash flows.
- Focus: relationship management over broad marketing
- Ops: maintain SLAs, minimize churn
- Finance: protect pricing, maximize cash extraction
Reanalysis/updated reports on legacy cases
Reanalysis/updated reports on legacy cases are cash cows: small lab effort delivers meaningful incremental billing where payers permit, with 2024 internal metrics showing ~200 USD average incremental charge and ~15% incremental revenue on eligible cohorts; clinicians value new insights without fresh samples and demand is steady, so systematize reminders and billing to keep the flywheel turning.
- Effort: low
- Incremental billing: ~200 USD (2024)
- Revenue uplift: ~15% (2024 cohorts)
- Demand: steady; automate reminders/billing
Hereditary germline panels: stable margins, USD 2.0B market, steady per-test profit
Hereditary germline panels are Fulgent cash cows amid stable 2024 guidelines; market ~USD 2.0B (2024) and high clinician awareness sustain margins. Routine small panels deliver steady per-test profitability with low COGS; utilization is flat but reliable. Ancillary cytogenetics reimburse $300–1,200 (2024); reanalysis yields ~USD 200 average incremental charge (~15% uplift).
| Segment | 2024 metric | Margin/notes |
|---|---|---|
| Hereditary panels | Market USD 2.0B | High awareness, stable demand |
| Small panels | Flat growth | Low COGS, steady profit |
| Cytogenetics | Reimb USD 300–1,200 | Predictable volumes |
| Reanalysis | ~USD 200 avg | ~15% revenue uplift |
What You See Is What You Get
Fulgent BCG Matrix
The file you’re previewing is the exact Fulgent BCG Matrix you’ll receive after purchase — no watermarks, no demo slides, just the finished, professionally formatted report. It’s built for immediate use: edit, print, or drop straight into your pitch deck without fuss. Once bought, the same document is delivered to your inbox, ready for strategic planning or client presentations. No surprises, just clean, market-tested analysis you can act on.
